GSK price news: Capital management and easing litigation support stable yield near 3.5%

Traders Union
All News
Financial News
GSK rises 0.36% today to GBX 1,790

Highlights

GSK completed the purchase of 170,000 ordinary shares through its BNP Paribas-led buyback, supporting its ongoing £2 billion capital management initiative.
GSK's treasury now holds 256,464,844 shares out of 4,058,966,266 in issue, while its ex-dividend date just passed and yield remains near 3.5%.
Regulatory progress for top drugs continues and Zantac litigation risks are easing, while GSK Egypt's EPS fell to EGP 0.36 for the first nine months of 2025.

Share buybacks, regulatory progress and Zantac overhang shape near-term outlook

GSK has executed the purchase of 170,000 ordinary shares as part of its ongoing share buyback program in partnership with BNP Paribas, supporting a larger £2 billion capital management initiative. The company now holds 256,464,844 shares in treasury out of 4,058,966,266 shares in issue, and recently concluded its ex-dividend date with a stable yield near 3.5%. Regulatory progress for key drugs continues, and legacy Zantac litigation is easing, though still present. GSK Egypt’s reported earnings declined, with EPS falling to EGP 0.36 for the first nine months of 2025.

Bullish alignment and upward momentum as price clears technical floors

GBX 1,790.50 is trading above the MA-20 (GBX 1,734.68), MA-50 (GBX 1,625.94), and MA-200 (GBX 1,482.63), confirming a bullish structure across all key timeframes. The nearest dynamic support is now at the Kijun level from the Ichimoku (GBX 1,713.25), while resistance may be encountered near the MA-5 (GBX 1,802.90) or the next round level at GBX 1,800.

Upward bias likely as scenario favors resistance breakout over correction

For the next 5 trading days, the expected range is GBX 1,789.00 to GBX 1,798.50. There is a very high probability (more than 80%) of an upward move, while a decline is much less likely. The baseline scenario envisions sideways action between support at the Ichimoku Kijun (GBX 1,713.25) and resistance near GBX 1,800. A bullish scenario would see the price break above resistance, aiming for new highs beyond GBX 1,800. A bearish scenario could unfold if the price drops below the Kijun support, potentially leading to a corrective retreat toward the mid-GBX 1,700s.

Anton Kharitonov, analyst at Traders Union, notes that GSK maintains a bullish structure above key moving averages, but sees lingering risks. He highlights that share buybacks and regulatory progress support sentiment, while ongoing Zantac litigation and weak Egypt earnings cast a shadow. The analyst remains cautious, eyeing GBX 1,713.25 as crucial support and GBX 1,800 as resistance. "Base case remains sideways to slightly higher, but any break below Kijun support would shift my bias to defensive," Kharitonov says.

Previously it was noted that GSK continued its share buyback activity and formed a new partnership to advance tuberculosis treatment. The technical analysis discussed overbought momentum alongside robust trend based on market signals.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.